SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bunn PA Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998; 4: 10871100.
  • 2
    Murren JR. Rationale for non-platinum chemotherapy in advanced non-small cell lung cancer. Oncology. 2001; 15 (Suppl 7): 2934.
  • 3
    Hainsworth JD, Burris HA, Erland JB, et al. Phase I/II trial of paclitaxel by one-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced non-small cell lung cancer. Cancer. 1999; 85: 12691276.
  • 4
    Hainsworth JD, Burris HA, Morrissey LH, et al. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase trial of the Minnie Pearl Cancer Research Network. Cancer J Sci Am. 2000; 6: 151156.
  • 5
    Hainsworth JD, Burris HA, Litchy S, et al. Gemcitabine and vinorelbine in second-line treatment of non-small cell carcinoma patients: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2000; 88: 13531358.
  • 6
    Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract, a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001; 19: 30183024.
  • 7
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 8
    Kelly K, Crowley J, Bunn PA Jr., et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer, a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 32103218.
  • 9
    Seiferheld W, Scott C, Byhardt RW, Curran WJ. The triangle test reduces time to decision in Phase II trials of survival: results from the radiation therapy oncology group (RTOF). Proc Soc Clin Trials. 1999; 20: 54s.
  • 10
    Bellissant E, Benichou J, Chastang C. Application of the triangular test to Phase II cancer clinical trials. Stat Med. 1990; 9: 907917.
  • 11
    Krajnik G, Mohn-Staudner A, Thaler J, et al. Vinorelbine-gemcitabine in advanced non-small cell lung cancer (NSCLC): an AASLC Phase II trial. Austrian Association for the Study of Lung Cancer. Ann Oncol. 2000; 11: 993998.
  • 12
    Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001; 31: 277284.
  • 13
    Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 2000; 18: 25292536.
  • 14
    Gridelli C, Perrone F, Cigolari S, et al. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients [abstract 1230]. Proc Am Soc Clin Oncol. 2001; 20: 308a.
  • 15
    Van Meerbeeck JP, Smit EF, Lianes P, et al. An EORTC randomized Phase II trial of three chemotherapy regimens in advanced non-small cell lung cancer [abstract 1228]. Proc Am Soc Clin Oncol. 2001; 20: 308a.
  • 16
    Alberola V, Camps C, Provencia M, et al. Cisplatin/gemcitabine versus cisplatin/gemcitabine/vinorelbine versus sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine in advanced non-small cell lung cancer: results of a Spanish Lung Cancer Group Phase III trial [abstract 1229]. Proc Am Soc Clin Oncol. 2001; 20: 308a.